Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
José L Fachi *Department of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-1035-5193
Tihana Trsan *Department of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-7549-2885
Cristiane SéccaDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-4433-8962
Sarah de OliveiraDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-9449-9740
Vinícius R RodovalhoBioinformatics Laboratory, National Laboratory for Scientific Computation (LNCC), Petrópolis, Brazil.ORCID 0000-0003-4216-7143
Patrick Fernandes RodriguesDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-0214-0627
Wandy L BeattyDepartment of Molecular Microbiology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-0715-7361
Raki SudanDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0002-9101-818X
Shitong WuDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-6966-1008
Bishan BhattaraiDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0009-0003-1263-8554
Santosh K PandaDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-8884-3050
Marina CellaDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-1230-1313
Susan GilfillanDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0003-1672-0996
Marco ColonnaDepartment of Pathology and Immunology, Washington University in St. Louis, School of Medicine, Saint Louis, MO, USA.ORCID 0000-0001-5222-4987
Funding
Mucosal Immune Defense Mechanisms of the Urinary BladderR01DK132327 · NIDDK · WASHINGTON UNIVERSITY · PI MARCO COLONNA, SCOTT J. HULTGREN · 2023 to 2026
$2.5M
MICROBIOTA-DEPENDENT CONTROL OF CLOSTRIDIUM DIFFICILE: THE ROLE OF ACETATE AND IL-22 BINDING PROTEINR01DK126969 · NIDDK · WASHINGTON UNIVERSITY · PI COLONNA, MARCO · 2021 to 2024
$1.6M
Clinical and Translational Science Award UL1TR000448Institute of Clinical and Translational SciencesNational Science Foundation No. DBI-1827534NCI NIH HHS #P30 CA91842NCRR NIH HHSNIDDK NIH HHS R01 DK126969NIDDK NIH HHS R01 DK132327NIH HHS R01DK126969NIH HHS R01DK132327NIH HHS S10 OD032131NIH HHS WLC6313040077Pew Charitable Trusts 00035299São Paulo Research Foundation 2023/00393-4São Paulo Research Foundation FAPESP 2017/06577-9
6 · The paper itself
Abstract
LINGO4 is a leucine-rich repeat and immunoglobulin-like domain-containing transmembrane protein encoded immediately adjacent to Rorc, the gene for RORγt, raising the possibility that it contributes to the biology of RORγt+ lymphocytes. However, its impact on these cells and resistance to enteric infections has remained unknown. Here, we identify LINGO4 as a critical regulator of group 3 innate lymphoid cells (ILC3s). Lingo4-/- ILC3s exhibit a profound, cell-intrinsic defect in IL-22 production linked to impaired STAT3 activation, mitochondrial dysfunction, elevated ROS, and increased apoptosis. In vivo, Lingo4 deficiency also drives a dysbiotic gut microbiota, resulting in an additional, microbiota-dependent loss of ILC3s. These combined defects increase susceptibility to Clostridioides difficile and Citrobacter rodentium, whereas IL-22 reduction in Lingo4-/- mice confers protection against Salmonellatyphimurium. Immunoprecipitation of tagged LINGO4 reveals interaction networks enriched in mitochondrial pathways, providing mechanistic insight into its role in ILC3 metabolic fitness and intestinal immunity.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
LINGO4 coordinates ILC3-intrinsic IL-22 production and microbiota-mediated ILC3 homeostasis. · full record | OpenQuestion